BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27063274)

  • 1. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease.
    Ganesh S; Rustgi VK
    Clin Liver Dis; 2016 May; 20(2):351-64. PubMed ID: 27063274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and emerging therapies in nonalcoholic fatty liver disease.
    Kashi MR; Torres DM; Harrison SA
    Semin Liver Dis; 2008 Nov; 28(4):396-406. PubMed ID: 18956296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis.
    Corey KE; Rinella ME
    Dig Dis Sci; 2016 May; 61(5):1387-97. PubMed ID: 26942734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy of nonalcoholic steatohepatitis: Reflections on the existing evidence.
    Tang JT; Mao YM
    J Dig Dis; 2017 Nov; 18(11):607-617. PubMed ID: 29106066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic therapy of non-alcoholic steatohepatitis.
    Ratziu V; Zelber-Sagi S
    Clin Liver Dis; 2009 Nov; 13(4):667-88. PubMed ID: 19818312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review article: Drug therapy for non-alcoholic fatty liver disease.
    Comar KM; Sterling RK
    Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Golabi P; Bush H; Younossi ZM
    Clin Liver Dis; 2017 Nov; 21(4):739-753. PubMed ID: 28987260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease.
    Paredes AH; Torres DM; Harrison SA
    Clin Liver Dis; 2012 May; 16(2):397-419. PubMed ID: 22541706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment.
    Bugianesi E; Marzocchi R; Villanova N; Marchesini G
    Best Pract Res Clin Gastroenterol; 2004 Dec; 18(6):1105-16. PubMed ID: 15561641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. State of the art: treatment of nonalcoholic steatohepatitis.
    Pearlman M; Loomba R
    Curr Opin Gastroenterol; 2014 May; 30(3):223-37. PubMed ID: 24717764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current treatment options for nonalcoholic fatty liver disease.
    Shetty A; Syn WK
    Curr Opin Gastroenterol; 2019 May; 35(3):168-176. PubMed ID: 30844893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease: new treatments.
    Hardy T; Anstee QM; Day CP
    Curr Opin Gastroenterol; 2015 May; 31(3):175-83. PubMed ID: 25774446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
    Said A; Akhter A
    Ann Hepatol; 2017; 16(4):538-547. PubMed ID: 28611274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omega-3 polyunsaturated fatty acid and ursodeoxycholic acid have an additive effect in attenuating diet-induced nonalcoholic steatohepatitis in mice.
    Kim JK; Lee KS; Lee DK; Lee SY; Chang HY; Choi J; Lee JI
    Exp Mol Med; 2014 Dec; 46(12):e127. PubMed ID: 25523099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy for nonalcoholic fatty liver disease.
    Moseley RH
    J Clin Gastroenterol; 2008 Apr; 42(4):332-5. PubMed ID: 18277910
    [No Abstract]   [Full Text] [Related]  

  • 18. NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.
    Caldwell S
    Clin Mol Hepatol; 2017 Jun; 23(2):103-108. PubMed ID: 28494529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease.
    Imprialos K; Stavropoulos K; Bouloukou S; Kerpiniotis G; Karagiannis A; Doumas M
    Curr Vasc Pharmacol; 2018; 16(3):276-288. PubMed ID: 28676020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease: pharmacologic and surgical options.
    Parikh N; Ahmad J
    Gastroenterol Clin North Am; 2011 Sep; 40(3):541-59. PubMed ID: 21893273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.